ArticleTherapeutic innovation & regulatory science2026
When Randomization Assigns a Starting Strategy: An Estimand-Led Framework for Frozen Embryo Transfer Trials.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Randomized trials may assign a treatment strategy rather than a fixed, uninterrupted exposure. Frozen embryo transfer (FET) provides a clear example: women can be randomized to start natural, modified natural, or artificial endometrial preparation, while cancellation and rescue artificial preparation change the care subsequently received. Unless the estimand is explicit, a terminal livebirth comparison can be mistaken for a comparison of uninterrupted protocols. Using the randomized trial by Ho et al. as a worked example, this Analysis examines how intercurrent events - particularly cancellation, delayed transfer, and rescue switching - shape the clinical question and interpretation. It distinguishes a starting-strategy estimand that uses a treatment-policy strategy for these events from completed-protocol and hypothetical no-switch estimands; it also develops patient-centered efficacy variables and denominator-aligned safety estimands. The framework recommends that FET trials prespecify the primary estimand, report cancellation and switching as core outcomes, include time and burden, align safety outcomes with biologically meaningful denominators, and document operational rules. Here, strategy denotes the intervention assigned at randomization, whereas pathway denotes the care sequence realized after assignment. This FET framework may serve as a prototype for other randomized trials of treatment algorithms, but generalization requires setting-specific estimand and intercurrent-event specification.
Indexed as
Identifiers
42850430What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.